| Name | AZD0095 |
|---|---|
| Synonyms |
[1,2,4]Triazolo[1,5-a]pyrimidine, 2,5,7-trimethyl-6-[[(3R)-1-[4-[6-(4-morpholinylmethyl)-3-pyridazinyl]phenyl]-3-pyrrolidinyl]oxy]
(R)-4-((6-(4-(3-((2,5,7-Trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)oxy)pyrrolidin-1-yl)phenyl)pyridazin-3-yl)methyl)morpholine AZD0095, 10 mM in DMSO |
| Description | AZD0095 is a selective and orally active MCT4 inhibitor (IC50: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205)[1]. |
|---|---|
| Related Catalog | |
| Target |
MCT4:1.3 nM (IC50) |
| In Vitro | AZD0095 (0-50 µM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖,IC50 为 26 nM[1]。 |
| In Vivo | AZD0095 (100 mg/kg, 口服,一天两次) 与 Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长[1]。 Animal Model: Murine NCI-H358 xenograft[1] Dosage: 100 mg/kg together with Cediranib (3 mg/kg) Administration: Oral administration (p.o.) Result: Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone. |
| References |
| Molecular Formula | C27H32N8O2 |
|---|---|
| Molecular Weight | 500.60 |